Category - Developments

Developments

Allarity secures first commercial agreement under new CLIA laboratory services strategy

Allarity Therapeutics (NASDAQ: ALLR) has announced its first revenue-generating contract under its newly established Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory services strategy, which is...

October 30, 2026

Developments

Profound and Cook in potentially transformational iMRI partnership for TULSA-PRO

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced that it has entered into a supply and distribution agreement with the iMRI Division of closely held Cook Medical to expand U.S. sales of its TULSA-PRO system...

October 30, 2026

Developments

Perimeter’s Claire OCT earns multiple industry honors and mentions including TIME Best Inventions of 2026

Perimeter Medical Imaging AI’s (TSX-V: PINK; OTCQX: PYNKF) Claire OCT has received a special mention in TIME’s Best Inventions of 2026, earning national recognition for its approach to helping surgeons identify...

October 30, 2026

Developments

Valion advances Entolimod into U.S. government-funded efficacy on the heels of positive safety results

Valion Bio (NASDAQ: VBIO) has announced that the Armed Forces Radiobiology Research Institute (AFRRI) will evaluate the therapeutic efficacy of Entolimod in a post-radiation treatment model designed to assess whether...

October 30, 2026

Developments

South Carolina nuclear-site fire further underscores potential for Valion’s Entolimod needle-free radiation countermeasure

An October 28, 2026 fire at a South Carolina complex that once produced plutonium and tritium for nuclear weapons is a timely reminder of the importance of resilient emergency preparedness for potential radiological and...

October 29, 2026

Developments

Celularity and Vesalius collaborate for U.S. manufacturing of Peptual peptide APIs

Celularity (NASDAQ: CELU) and Vesalius Longevity Labs (CSE: VLAB) have announced an exclusive manufacturing agreement to establish a dedicated, first-of-its-kind, U.S. final stage API manufacturing and supply platform...

October 29, 2026

Developments

Azitra expands ATR-04 Phase 1/2 trial patient eligibility

Azitra (NYSE American: AZTR) has announced amendments to its ongoing Phase 1/2 clinical trial of ATR04-484 that significantly expand patient eligibility to include individuals with rash associated with KRAS and MEK...

October 29, 2026

Developments

Valion releases final data from U.S. government-funded Entolimod study

Valion Bio (NASDAQ: VBIO) has announced final data from a safety study funded by the National Institute of Allergy and Infectious Diseases (NIAID)/Radiation and Nuclear Countermeasures Program (RNCP) that evaluated its...

October 28, 2026

Developments

FireFly strengthens BCI growth strategy with commercially available platform

FireFly Neuroscience (NASDAQ: AIFF) has provided an update on its non-invasive brain-computer interface (BCI) strategy, highlighting the role of its commercially available Versus platform in pursuing the human...

October 28, 2026

Developments

Clearmind completes patient recruitment for first AUD cohort of CMND-100 trial

Clearmind Medicine (NASDAQ: CMND) announced the completion of patient recruitment for the first segment of Part B of its ongoing Phase 1/2a clinical trial evaluating CMND-100 in patients with moderate-to-severe alcohol...

October 28, 2026

Category - Developments

Subscribe